Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2397-768X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14) ; volume:6 ; number:1 ; day:19 ; month:10 ; year:2022 ; pages:1-7 ; date:12.2022
npj precision oncology ; 6, Heft 1 (19.10.2022), 1-7, 12.2022
- Creator
-
Nguyen, Nina
Chaudhry, Sana
Totiger, Tulasigeri M.
Diaz, Robert
Roberts, Evan
Montoya, Skye
Pardo, Gabriel
Pardo, Alejandro
Afaghani, Jumana
Affer, Maurizio
Jahn, Jacob
Bradley, Terrence
Maura, Francesco
Kazandjian, Dickran
Bilbao, Daniel
Chapman, Jennifer
Landgren, Ola
Hoffman, James
Taylor, Justin
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41698-022-00315-2
- URN
-
urn:nbn:de:101:1-2023010421100646815644
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nguyen, Nina
- Chaudhry, Sana
- Totiger, Tulasigeri M.
- Diaz, Robert
- Roberts, Evan
- Montoya, Skye
- Pardo, Gabriel
- Pardo, Alejandro
- Afaghani, Jumana
- Affer, Maurizio
- Jahn, Jacob
- Bradley, Terrence
- Maura, Francesco
- Kazandjian, Dickran
- Bilbao, Daniel
- Chapman, Jennifer
- Landgren, Ola
- Hoffman, James
- Taylor, Justin
- SpringerLink (Online service)
Other Objects (12)
Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients
Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Accelerated single cell seeding in relapsed multiple myeloma
Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity
Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Management of Relapsed and Refractory Multiple Myeloma: Recent advances
Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients
Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Accelerated single cell seeding in relapsed multiple myeloma
Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity
Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Management of Relapsed and Refractory Multiple Myeloma: Recent advances
Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy
Exposure-response relationships of venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory t(11;14) multiple myeloma patients
Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature
Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia
Accelerated single cell seeding in relapsed multiple myeloma
Pleural effusion in 11:14 translocation q1 multiple myeloma in the setting of proteasome inhibitor presents therapeutic complexity
Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Management of Relapsed and Refractory Multiple Myeloma: Recent advances
Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression